RE:Value to shareholderswinnerswing wrote: Someone can explain why value to shareholders has been created again during Q4 2022 while a net loss has been recorded?
Q4 is typically the weakest quarter. Individual quarters are lumpy. You need to look at annual results. 2022 was another record year with 10% growth which is consistent with the historic growth rate of the last decade.
- "Cash generated from operations of $6,637,000, for the full year 2022 compared to $3,510,000 in 2021." News release
The pipeline continues to advance from approval for the avenanthramide clinical trial, to the fibrosis drug which is before a go/no go clinical trial decision in the summer. The bioavailability results were also exceptional vs. the gold standard.